Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

BMC Rheumatology

Research Article

Olida Cecen¹  Deniz Maktav Celikmen¹  Muhammed Mert Sonkaya¹  Isilsu Ezgi Uluisik¹  Yavuz Furuncuoglu¹  Fulya Cosan²  Ozlem Unay Demirel³  Timucin Avsar⁴  Demet Yalcin⁵  Erkan Ceylan⁶  Osman Kara⁷ 

[1] Faculty of Medicine, Department of Internal Medicine, Bahcesehir University, Istanbul, Turkey;Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Bahcesehir University, Istanbul, Turkey;Faculty of Medicine, Department of Medical Biochemistry, Bahcesehir University, Istanbul, Turkey;Faculty of Medicine, Department of Medical Biology, Bahcesehir University, Istanbul, Turkey;Faculty of Medicine, Department of Medical Microbiology, and Infectious Diseases, Istinye University, Istanbul, Turkey;Medical Park Goztepe Hospital, Department of Chest Diseases, Bahcesehir University, Istanbul, Turkey;Medical Park Goztepe Hospital, Department of Hematology, Bahcesehir University, Istanbul, Turkey;

关键词: Anti-spike IgG;    Anti-spike IgA;    BNT162b2;    CoronaVac;    Immunosuppressive;    Neutralizing antibody activity;   

DOI  :  10.1186/s41927-023-00342-x

 received in 2022-09-29, accepted in 2023-06-20,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study was to examine the differences in anti-Spike IgG, anti-Spike IgA, and neutralizing antibody (NAb) activity between the inactive CoronaVac vaccine and the mRNA-based BNT162b2 vaccine in IS patients.MethodA total of 441 volunteers, including 104 IS patients, 263 healthy controls (HC), who received two doses of CoronaVac or BNT162b2, and 74 unvaccinated patients with a history of SARS-CoV-2 infection, were included in the study. Anti-spike IgG, IgA, and NAb activity were investigated.ResultsImmunogenicity with BNT162b2 was higher than with CoronaVac, but in IS groups, it was lower than HC (CoronaVac-IS: 79.3%, CoronaVac-HC: 96.5%, p < 0.001; BNT162b2-IS: 91.3%, BNT162b2-HC: 100%, p = 0.005). With CoronaVac, anti-Spike IgG levels were significantly lower than BNT162b2 (CoronaVac-IS: 234.5AU/mL, CoronaVac-HC: 457.85AU/mL; BNT162b2-IS: 5311.2AU/mL, BNT162b2-HC: 8842.8AU/mL). NAb activity in the BNT162b2 group was significantly higher. NAb and anti-Spike IgG levels were found to be correlated. Among the IS group, a significantly lower response to the vaccines was observed when using rituximab. IgA levels were found to be lower with CoronaVac.ConclusionsAlthough immunogenicity was lower in IS patients, an acceptable response was obtained with both vaccines, and significantly higher anti-Spike IgG, anti-Spike IgA, and NAb activity levels were obtained with BNT162b2.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_266_Article_IEq55.gif

40517_2023_266_Article_IEq54.gif

40517_2023_266_Article_IEq49.gif

40517_2023_266_Article_IEq46.gif

40517_2023_266_Article_IEq44.gif

40517_2023_266_Article_IEq41.gif

40517_2023_266_Article_IEq37.gif

40517_2023_266_Article_IEq35.gif

40517_2023_266_Article_IEq28.gif